{"id":"myl-1401o","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Hypertension"},{"rate":"15–25","effect":"Proteinuria"},{"rate":"5–15","effect":"Bleeding/hemorrhage"},{"rate":"5–10","effect":"Thromboembolic events"},{"rate":"1–2","effect":"Gastrointestinal perforation"},{"rate":"2–5","effect":"Wound healing complications"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bevacizumab biosimilar, MYL-1401O binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels supplying tumors. By blocking VEGF, the drug starves tumors of their blood supply, slowing or halting tumor growth. This mechanism is used across multiple solid tumor indications where angiogenesis is a critical driver of progression.","oneSentence":"MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:21.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-squamous non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":"HER2-positive Breast Cancer, LMD","enrollment":30},{"nctId":"NCT02472964","phase":"PHASE3","title":"Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2012-07","conditions":"Breast Cancer","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hercules"],"phase":"phase_3","status":"active","brandName":"MYL- 1401O","genericName":"MYL- 1401O","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}